Case with Ali Salanti
All pioneering treatment stands on the shoulders of strong basic research.
Danish health research is among the best in the world. It is essential to attract the brightest minds and have the best working conditions in order to remain one of the front-runners.
Therefore, it is vital that public funding for research from e.g. the Danish National Research Foundation, the Danish Council for Independent Research and the EU continues to channel funds to the most original, innovative research ideas.
Historically, independent research has been able to deliver a number of major breakthroughs that have streamlined the health service through improved prevention, diagnosis, new treatment methods, new databases and new technology.
Freedom, curiosity and impact
Denmark is recognized as one of the world leaders in basic research. The entire ecosystem of Danish research is founded on strong basic research as the bedrock upon which the scientific community can develop.
Independent funding from the Danish National Research Foundation, the Danish Council for Independent Research and the EU make up the majority of the financial resources that fund research at the Faculty for Health and Medical Sciences.
Grants go to the most talented researchers and make it possible to pursue original ideas.
Basic research expands human understanding. Not all of our projects result in ground-breaking results, so a certain amount of fortitude is necessary to take risks with this type of research. Nevertheless, most of the projects uncover new knowledge that contributes to both small and major discoveries in prevention and treatment.
This new knowledge cuts costs in the health sector and gives leverage in other areas, e.g. the medicinal industry.
”The fundamental discoveries that are now a major part of our core business in Denmark have been made at the universities. We develop and market medicines on the basis of these discoveries. We have never been involved in making the first basic breakthroughs here at Novo Nordisk. We often receive all the praise and glory when the honour should really go to the universities and the cooperation there is between us”, says Mads Krogsgaard Thomsen, Chief Science Officer at Novo Nordisk AS.